Kurs
-4,42%
Likviditet
5,13 MNOK
Kalender
| Tid* | ||
| 2026-02-13 | N/A | Bokslutskommuniké 2025 |
| 2025-11-07 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-22 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-23 | N/A | Årsstämma |
| 2025-05-16 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-14 | N/A | Bokslutskommuniké 2024 |
| 2024-11-08 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-16 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-13 | - | X-dag ordinarie utdelning HBC 0.00 NOK |
| 2024-05-10 | - | Årsstämma |
| 2024-02-09 | - | Bokslutskommuniké 2023 |
| 2024-01-04 | - | Extra Bolagsstämma 2024 |
| 2023-11-10 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-12 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-02 | - | X-dag ordinarie utdelning HBC 0.00 NOK |
| 2023-04-28 | - | Årsstämma |
| 2023-02-10 | - | Bokslutskommuniké 2022 |
| 2022-11-11 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-30 | - | Extra Bolagsstämma 2022 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-06 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-02 | - | X-dag ordinarie utdelning HBC 0.00 NOK |
| 2022-04-29 | - | Årsstämma |
| 2022-02-04 | - | Bokslutskommuniké 2021 |
| 2021-12-03 | - | Extra Bolagsstämma 2021 |
| 2021-11-05 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-21 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-26 | - | X-dag ordinarie utdelning HBC 0.00 NOK |
| 2021-04-23 | - | Årsstämma |
| 2021-02-05 | - | Bokslutskommuniké 2020 |
| 2020-11-11 | - | Extra Bolagsstämma 2020 |
| 2020-10-30 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-26 | - | X-dag ordinarie utdelning HBC 0.00 NOK |
| 2020-05-25 | - | Årsstämma |
| 2020-05-15 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-07 | - | Bokslutskommuniké 2019 |
| 2019-11-01 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-30 | - | Extra Bolagsstämma 2019 |
| 2019-08-30 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-10 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-29 | - | X-dag ordinarie utdelning HBC 0.00 NOK |
| 2019-04-26 | - | Årsstämma |
| 2019-02-08 | - | Bokslutskommuniké 2018 |
| 2018-11-02 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-16 | - | Extra Bolagsstämma 2018 |
| 2018-05-09 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-30 | - | X-dag ordinarie utdelning HBC 0.00 NOK |
| 2018-04-27 | - | Årsstämma |
| 2018-03-16 | - | Bokslutskommuniké 2017 |
| 2017-11-15 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-25 | - | Årsstämma |
| 2017-05-12 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-17 | - | Bokslutskommuniké 2016 |
| 2016-11-18 | - | Kvartalsrapport 2016-Q3 |
| 2016-09-20 | - | Extra Bolagsstämma 2016 |
| 2016-08-31 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-20 | - | Årsstämma |
| 2016-05-20 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-18 | - | Bokslutskommuniké 2015 |
| 2015-11-13 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-13 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-22 | - | Årsstämma |
| 2015-04-30 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-27 | - | Bokslutskommuniké 2014 |
| 2014-05-02 | - | Extra Bolagsstämma 2014 |
| 2013-12-27 | - | Extra Bolagsstämma 2013 |
| 2013-06-13 | - | Kapitalmarknadsdag 2013 |
| 2012-10-31 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-22 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-25 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-29 | - | Bokslutskommuniké 2011 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Kristin Fjellby Grung, Chair of the Board of Hofseth BioCare ASA, has informed the Board of Directors that she will resign from the position on 31 March 2024, as she will assume a position as judge in the District Court of Møre and Romsdal and will therefore not be able to continue to serve in the position as Chair of the Board.
Grung has been a member of the Board of Directors since December 2020, and assumed the position as Chair in April 2022. The Board would like to thank Grung for her services for Hofseth BioCare in this period.
Appointment of a new Chair of the Board will be proposed to the Company's annual general meeting, to be held on 10 May 2024. In the interim period, Roger Hofseth will function as the Chair of the Board of Directors.
For further information, please contact:
Jon Olav Ødegård, CEO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no
About Hofseth BioCare ASA:
HBC is a Norwegian consumer and pet health ingredient supplier and an incubator for new pharmaceutical drug leads. Research is ongoing to identify the individual elements within its ingredients that modulate inflammation and the immune response with pre-clinical studies ongoing in multiple clinics and university research labs. Lead clinical and pre-clinical candidates are focused on developing an oral treatment for inflammatory disease driven by eosinophils (a type of white blood cell). Clinical trial work with the oil is ongoing to ameliorate lung inflammation in eosinophilic asthma and COPD ("smokers lung").
Other leads are focused on using the Company's bioactive peptides as a Medical Food for the protection of the Gastro- Intestinal (GI) system against inflammation (including ulcerative colitis and the orphan condition necrotizing enterocolitis). The Company is founded on the core values of sustainability, optimal utilization of natural resources and full traceability. Through innovative and patent protected hydrolysis technology, HBC can preserve the quality of the lipids, proteins and calcium from fresh salmon off-cuts.
HBC's headquarters are in Ålesund, Norway with offices in Oslo, London, Zürich, New Jersey and Palo Alto, CA.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.